CN110464808A - Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions and its preparation method and application - Google Patents
Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions and its preparation method and application Download PDFInfo
- Publication number
- CN110464808A CN110464808A CN201910858450.7A CN201910858450A CN110464808A CN 110464808 A CN110464808 A CN 110464808A CN 201910858450 A CN201910858450 A CN 201910858450A CN 110464808 A CN110464808 A CN 110464808A
- Authority
- CN
- China
- Prior art keywords
- group
- weight
- parts
- lipid
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 36
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 32
- 241000124033 Salix Species 0.000 claims abstract description 32
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 31
- 229940038580 oat bran Drugs 0.000 claims abstract description 31
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims description 19
- 230000000968 intestinal effect Effects 0.000 claims description 16
- 235000013402 health food Nutrition 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 30
- 241000894006 Bacteria Species 0.000 abstract description 27
- 210000000577 adipose tissue Anatomy 0.000 abstract description 25
- 241000186000 Bifidobacterium Species 0.000 abstract description 24
- 230000004584 weight gain Effects 0.000 abstract description 24
- 235000019786 weight gain Nutrition 0.000 abstract description 24
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 22
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 22
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 22
- 108090001005 Interleukin-6 Proteins 0.000 abstract description 21
- 210000001550 testis Anatomy 0.000 abstract description 20
- 239000004310 lactic acid Substances 0.000 abstract description 19
- 235000014655 lactic acid Nutrition 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 16
- 108091006374 cAMP receptor proteins Proteins 0.000 abstract description 15
- 150000002632 lipids Chemical class 0.000 abstract description 15
- 230000002757 inflammatory effect Effects 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 4
- 241000700159 Rattus Species 0.000 description 39
- 235000019197 fats Nutrition 0.000 description 32
- 102000007330 LDL Lipoproteins Human genes 0.000 description 23
- 108010007622 LDL Lipoproteins Proteins 0.000 description 23
- 239000013641 positive control Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 12
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 7
- 229960001243 orlistat Drugs 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 6
- 244000005709 gut microbiome Species 0.000 description 6
- 239000006041 probiotic Substances 0.000 description 6
- 235000018291 probiotics Nutrition 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 108700022737 rat Fat1 Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004900 laundering Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002956 ash Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions and its preparation method and application；The raw material of the composition is made of 5~80 parts of oat bran, 5~80 parts of Qingqian Willow leaf, 5~80 parts of mushroom and 5~80 parts of honeysuckle, and this method first mixes oat bran, Qingqian Willow leaf, mushroom and honeysuckle, obtains mixture；Then it soaks in water, decocts into mixture, filtering obtains the Chinese medicine composition.The present composition can lose weight, reduce weight gain, reduce body fat weight (testis and perinephric fat pad), improve Bifidobacterium and lactic acid bacteria ratio, it adjusts inflammatory factor (TNF-α, IL-6, CRP), improve blood lipid (TC, TG, LDL, HDL), it can be used for Weight-reducing and lipid-lowering, significant effect is better than the effect of each single dose.
Description
Technical field
The present invention relates to technical field of health care food, and in particular to a kind of Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions and its system
Preparation Method and application.
Background technique
In recent years, as continuous improvement of people's living standards, the increasingly quickening of rhythm of life, living habit are gradually to height
Calorie diet and the transformation of sitting posture life style, obese patient increase at an amazing speed in the world.Obesity is also very much
Chronic disease occur main inducing, can increase diabetes B, coronary heart disease, atherosclerosis, hypertension, fatty liver and certain
The morbidity and mortality of a little cancers etc..Therefore, fat to have become the public health problem paid attention to by scientific circles.
Some researches show that being often accompanied by intestinal bacilli illness in obese patient's body, and the intestinal flora of structural imbalance may be to lure
An important factor for sending out chronic disease a series of and occur.Therefore, classical symptom of the intestinal microflora imbalance as obese patient, in fertilizer
It must draw attention in fat disease correlation pharmacology study on mechanism.Bifidobacterium and lactic acid bacteria are that one kind is present in human intestine
Most representative enteral probiotics can improve human gastrointestinal tract function, restore colony balance in human body intestinal canal, form antibacterial
Biological barrier safeguards human health；It can also inhibit cholesterol absorption, there is reducing blood lipid, hypotensive activity.This prompt is in drug
It treats in fat study on mechanism, the effect of Bifidobacterium and lactic acid bacteria is to cannot be neglected.
Currently, pre- preventing obesity mainly uses two aspect of Western medicine and Chinese medicine:
Western medicine especially antibiotic usage (such as tetracycline antibiotics for oral administration) is improper, often destroys animal gastrointestinal tract
Normal Tiny ecosystem brings many adverse reactions, or even causes disease.And such case is seldom seen during application in TCM.No
Only in this way, adjusting by Chinese medicine, dysbacteriosis caused by antibiotic can also be made to be restored.Help containing polysaccharide component
Class Chinese medicine all has probiotic microorganisms and pathogenic microorganisms and fosters effect, but is substantially better than to the effect of fostering of probiotic microorganisms
Pathogenic microorganisms.Therefore, the produced metabolite of the probiotic microorganisms to grow fine inhibits the life of pathogenic microorganisms indirectly again
It is long.For example, Codonopsis pilosula polysaccharide can promote the growth of Bifidobacterium in vitro, to increase the metabolism of acetic acid, enhance Bifidobacterium
Colonization resistance.The compound mixture made of the tonifying Qi class Chinese medicine such as Radix Codonopsis, Poria cocos, Rhizoma Atractylodis Macrocephalae gavage mouse discovery, with gavage it is preceding compared with,
Lactic acid bacteria, bifidobacteria obviously increase, and enterococcus quantity significantly reduces.
Orlistat (Orlistat) is the drug that current minority is approved for treatment obesity, it was found that it is to fertilizer
Fat disease has significant curative effect, but has the more side effect reported and refer to orlistat, prompts orlistat that may influence gastrointestinal tract
Health and liver function；It has not been reported simultaneously and shows that orlistat has any adjustment effect to intestinal flora, this just ignores weight
The factor of becoming fat wanted；And when being discontinued, then weight gain is generated.There is dispute to the safety of orlistat at present.Therefore,
It is very urgent for the exploration of the drug for the treatment of obesity and Small side effects.
The valuable feature of theory of traditional Chinese medical science first is that organic conception, human body is one unified whole, interrelated between internal organs,
And it is indivisible with external environment.It is exactly with integrally-regulated for leading diagnosis and treatment that this idea embodies in the treatment.Body
The Chinese medicine and its prescription of existing group effect, will not be acted on as Western medicine naturally it is single or excessively biased, but it is Multiple-Equilibrium, complete
Coordinate in face.Undoubtedly to the overall status of body, the balance including intestinal microecology is all often very useful.Because good
Micro-ecological environment is undivided with the good general function state of human body.
Prebiotics, which refer to, to be not easy to be absorbed by Host Digestion, beneficial bacterium can be promoted raw by changing the growth conditions of microorganism
Long substance, including oligofructose, galactooligosaccharide, inulin and human milk oligosaccharides, resistant starch, pectin, Arabic wood are poly-
Sugared, full cereal, dietary fiber and the non-carbohydrate with adjusting intestinal flora effect.Prebiotics can be prebiotic for enteron aisle
Bacterium fermentation utilizes, and increases ancestral home probiotics, containment harmful bacteria, lowers body inflammatory state, improve glycolipid metabolism, adjust intestinal hormone
Element variation, so as to improve fat and obesity-related metabolic disturbance.
But safe and efficient weight-reducing is just rarely developed from balance intestinal Tiny ecosystem, each internal organs angle of internal body at present
Chinese traditional medicines depressing lipid prebiotics product, and this be exactly people there is an urgent need to.
Summary of the invention
It is an object of the invention to overcome the deficiencies of the prior art and provide a kind of Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions
And its preparation method and application.The composition can lose weight, reduce weight gain, reduce body fat weight (testis and kidney
Peripheral adipose pad), improve Bifidobacterium and lactic acid bacteria ratio, adjust inflammatory factor (TNF-α, IL-6, CRP), improve blood lipid
(TC, TG, LDL, HDL), can be used for preventing or improving weight and hyperlipidemia, and significant effect is better than the effect of each single dose.
To achieve the above object, a kind of Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions designed by the present invention, the composition
Raw material is made of oat bran, Qingqian Willow leaf, mushroom and honeysuckle, in parts by weight, the dosage of each raw material are as follows:
Further, in the composition, in parts by weight, the dosage of each raw material are as follows:
Still further, in the composition, in parts by weight, the dosage of each raw material are as follows:
The foundation that raw material of the present invention is selected:
Oat is sweet in flavor mild-natured, can control abnormal sweating.Oat is referred to as a kind of crop for curing the same treatment of food, dietotherapeutic.Oat it is exhausted
Most of water-soluble fibre is distributed on the oat bran after removing endosperm.Modern research shows that containing abundant in oat bran
Dietary fiber, beta glucan therein have significant functions of lowering blood-fat and reducing weight；Research at present also demonstrates that avenabeta glucosan can be with
As prebiotics, promote Bifidobacterium and lactobacter growth, and reduces Escherichia coli quantity.
Blue or green money willow is the distinctive rare tree species resource in China, and civil its blade of commonly using does tea, taste " sweetness ", according to " China
Book on Chinese herbal medicine " record the effect of Qingqian Willow leaf is with " promoting the production of body fluid to quench thirst, clearing away summerheat ".Modern pharmacology research discovery, blue or green money willow have
The various actives such as hypoglycemic, lowering blood pressure and blood fat, enhancing immunity of organisms, anti-oxidant, anti-aging, antibacterial, anticancer.
Mushroom, Compendium of Material Medica think mushroom " sweet, flat, nontoxic ", are a kind of food of food and medicine consangunity, have very high battalion
Feeding, medicinal and health value.Modern research shows that lentinan can adjust the enteric flora disturbance as caused by diet, it can be bright
The aobvious composition for changing intestinal flora, tends to intestinal flora unbalance in vivo normally, and then adjusts the enterobacteriaceae as caused by diet
The blood lipid and blood glucose target of obesity caused by group's disorder, can obviously reduce the content of plasma triglyceride level, and it is solid can to reduce gallbladder
The content of alcohol, low-density lipoprotein and free fatty acid.
Honeysuckle has the effects that significant clearing heat and detoxicating, antibacterial anti-inflammatory, and complex chemical composition has been reflected
Not Chu just have more than 70 kinds, research shows that honeysuckle is rich in the ingredients such as organic acid, volatile oil, flavonoids, with gold and silver
Flower is that the Chinese patent drug of main component development has been widely used in clinic.It recent studies have shown that, Honegsukle flower P.E can promote body
Inside and outside Bifidobacterium, lactobacillus growth.
In conclusion oat bran, mushroom, honeysuckle have the function of adjusting intestinal beneficial bacterium growth, oat bran, blueness
Money willow leaf, mushroom can reduce hyperlipidemia, and four taste compatibilities can enhance the effect of adjusting intestinal flora, reducing blood lipid.It is tried through the present invention
Verifying, the composition can lose weight, reduces weight gain, reduction body fat weight (testis and perinephric fat pad),
Improve Bifidobacterium and lactic acid bacteria ratio, adjust inflammatory factor (TNF-α, IL-6, CRP), improve blood lipid (TC, TG, LDL,
HDL), it can be used for Weight-reducing and lipid-lowering, significant effect is better than the effect of each single dose.
The preparation method of above-mentioned Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions, comprising the following steps:
1) oat bran, Qingqian Willow leaf, mushroom and honeysuckle are mixed first, obtains mixture
2) it soaks in water, decocts into mixture, filtering obtains the Chinese medicine composition.
Preferably, in the step 2), the dosage of water is 3~10 times of mixture；
The time of immersion is 0.25~2 hour,
The number of decoction is 1~5 time, and the time decocted every time is 1~4 hour.
The drug of intestinal flora Weight-reducing and lipid-lowering is adjusted in preparation the present invention also provides a kind of above-mentioned composition or health care is eaten
Application in product.
The present invention also provides a kind of drugs, including above-mentioned composition.The drug further includes pharmaceutically acceptable auxiliary material.
Preferably, the dosage form of the drug is paste, granule, pill, powder, tablet, capsule, oral agents or syrup
Agent.But the dosage form of drug is not limited to this, and those skilled in the art think feasible dosage form in protection scope of the present invention
Within.
The present invention also provides a kind of health foods, including above-mentioned composition.The health food further includes that can connect on food
The food additives received.
Preferably, the dosage form of the health food be granule, capsule, syrup, tablet, pulvis, soft sweets, emulsion or
Oral solution.But the dosage form of health food is not limited to this, and those skilled in the art think feasible dosage form of the invention
Within protection scope.
Beneficial effects of the present invention:
Chinese medicine composition of the invention is made of the raw material including oat bran, Qingqian Willow leaf, mushroom, honeysuckle, compatibility
Simply, Weight-reducing and lipid-lowering significant effect, and it is without side-effects.Test result shows that the present composition can lose weight, reduce weight
Weight gain reduces body fat weight (testis and perinephric fat pad), improves Bifidobacterium and lactic acid bacteria ratio, adjust inflammation because
Sub (TNF-α, IL-6, CRP), improve blood lipid (TC, TG, LDL, HDL), can be used for Weight-reducing and lipid-lowering, significant effect is better than each list
The effect of agent.
Specific embodiment
The present invention is described in further detail combined with specific embodiments below, so as to those skilled in the art understand that.
The preparation of 1 prebiotic compositions 1 of embodiment
1. raw material
50 parts of oat bran, 50 parts of Qingqian Willow leaf, 50 parts of mushroom, 50 parts of honeysuckle.
2. preparation method
Semen coicis, sea-buckthorn, Exocarpium Citri Rubrum, the mixing of licorice raw material medicine are taken, is soaked in water, amount of water is 8 times of bulk pharmaceutical chemicals weight, leaching
Steeping the time is 1 hour, is decocted 2 times, 2 hours every time, decoction liquor filtering, being concentrated into solid content was 80% to get of the present invention
Chinese medicine composition 1.
The preparation of 2 prebiotic compositions 2 of embodiment
1. raw material
20 parts of oat bran, 50 parts of Qingqian Willow leaf, 30 parts of mushroom, 10 parts of honeysuckle.
2. preparation method
The preparation method is the same as that of Example 1.
The preparation of 3 prebiotic compositions 3 of embodiment
1. raw material
30 parts of oat bran, 15 parts of Qingqian Willow leaf, 20 parts of mushroom, 5 parts of honeysuckle.
2. preparation method
The preparation method is the same as that of Example 1.
The preparation of 4 prebiotic compositions 4 of embodiment
1. raw material
10 parts of oat bran, 20 parts of Qingqian Willow leaf, 30 parts of mushroom, 10 parts of honeysuckle.
2. preparation method
The preparation method is the same as that of Example 1.
The preparation of 5 prebiotic compositions 5 of embodiment
1. raw material
5 parts of oat bran, 80 parts of Qingqian Willow leaf, 5 parts of mushroom, 80 parts of honeysuckle.
2. preparation method
The preparation method is the same as that of Example 1.
The preparation of 6 prebiotic compositions 6 of embodiment
1. raw material
80 parts of oat bran, 80 parts of Qingqian Willow leaf, 80 parts of mushroom, 80 parts of honeysuckle.
2. preparation method
The preparation method is the same as that of Example 1.
The preparation of 7 prebiotic compositions 7 of embodiment
1. raw material
80 parts of oat bran, 50 parts of Qingqian Willow leaf, 5 parts of mushroom, 50 parts of honeysuckle.
2. preparation method
The preparation method is the same as that of Example 1.
The preparation of 8 prebiotic compositions 8 of embodiment
1. raw material
5 parts of oat bran, 5 parts of Qingqian Willow leaf, 5 parts of mushroom, 5 parts of honeysuckle.
2. preparation method
The preparation method is the same as that of Example 1.
The preparation of 9 prebiotic compositions 9 of embodiment
1. raw material
20 parts of oat bran, 5 parts of Qingqian Willow leaf, 60 parts of mushroom, 60 parts of honeysuckle.
2. preparation method
The preparation method is the same as that of Example 1.
It is as follows to choose the progress of Chinese medicine prebiotic compositions 1~4 test experience prepared by above-described embodiment 1~4:
The effect experiment of 10 prebiotic compositions of embodiment treatment hyperlipidemia obesity
1. experimental material
(1) main agents
Model feed (is maintaining 15.0% sucrose of feed addition, 15.0% lard, suitable casein, calcium monohydrogen phosphate, stone
Powder buys raw material by oneself, is completed using Hubei University of Chinese Medicine's feed making method, is added by Hubei University of Chinese Medicine's Experimental Animal Center
Work is completed).Other than crude fat, moisture, crude protein, crude fat, crude fibre, coarse ash, calcium, phosphorus, the calcium of model feed: phosphorus is equal
Reach the national standard for maintaining feed.
Bioengineering Research Institute is built up in kit, Nanjing.
(2) experimental animal
SD rat, male, SPF grades, weight (180 ± 15) g is provided by Hubei University of Chinese Medicine's animal experimental center.
(3) key instrument
Electronic analytical balance, BS124S, German Startorius company；Microplate reader: Bio-Rad company, the U.S.；Ultralow temperature
Deep freezer, U.S. Thermo Fisher Scientific；Ultrapure water machine, Mill-Q II, Milipore, Bedford, MA,
USA；DDL-5 refrigerated centrifuge, Anting Scientific Instrument Factory, Shanghai.
2. test method
2.1 laundering period: rat feeding maintains feed to observe 5-7 days under barrier system.
2.2 modeling phases:
2 groups are randomly divided by weight after laundering period, 10 rats, which are given, maintains feed as blank control group, remaining
Rat gives high heat model feed.It records weekly to appetite, berley amount, surplus appetite, weighs in 1 time.
After feeding 2 weeks, the rat for giving high-calorie feed is sorted by weight gain, is eliminated the lower obesity of weight gain and is supported
Anti- rat.Give the fat Sensitive Rats filtered out to high-calorie feed again 6 weeks, blank control group gives maintenance feed simultaneously.
2.3 given the test agent are given:
After the modeling phase, fat Sensitive Rats are randomly divided into 6 groups by weight, respectively model control group, the positive is right
According to group and 5 sample sets.It records weekly to appetite, berley amount, surplus appetite, weighs in 1 time.Model control group, positive control
Group and sample sets give high heat model feed, and blank control group gives maintenance feed.Various dose is given in each sample group stomach-filling
Given the test agent, embodiment 1 low, middle and high dose groups 0.9g/kg, 1.8g/kg, 3.6g/kg, four kinds of single medicinal material high dose groups
3.8g/kg, administered volume 2.0ml/kg, positive controls rat oral gavage orlistat suspension 60mg/kg, model control group
Give equivalent 0.5% carboxymethylcellulose sodium solution with blank control group, given the test agent gives the time 6 weeks, is no more than 10 weeks.
3. Testing index
After the test, it weighs, calculates weight gain.1% yellow Jackets (0.5ml/100g BW) anesthesia, dissection
Perinephric fat pad, testis peripheral adipose are taken, and is weighed, fatty ester/weight ratio is calculated.
Measure inflammatory factor (TNF-α, IL-6, CRP) and blood lipid (TC, TG, LDL, HDL).
The culture and counting of intestinal flora.It takes 1g fresh excreta in sterile centrifugation tube, adds according to 1:9 (quality: volume)
Enter sterile PBS buffer dilution, vortex blending instrument mixes, and obtains 10-1 dilution.10-1 dilution is subjected to gradient dilution again,
Until obtaining 10-4,10-5 and 10-6 dilution.Tri- kinds of gradient dilution liquid coatings of 10-4,10-5 and 10-6 of 100 μ l are taken respectively
In on MRS agar medium (lactic acid bacteria), BBL agar medium (Bifidobacterium), each dilution does 3 parallel laboratory tests, whole
Interior completion in a process 30min.37 DEG C of incubation 48h, later carry out bacterium colony counting, be as a result expressed as CFU/ml (bacterium colony count before,
Picking feature bacterium colony first carries out ecological biochemical test, identifies the Pseudomonas).
4. statistical method
Variance analysis is generally used, but need to first carry out homogeneity test of variance by the program of variance analysis, variance is neat, calculates F
Value, F value < F0.05, conclusion: no significant difference between each group mean；F value >=F0.05, P≤0.05, with multiple experimental groups and one
The comparative approach two-by-two of mean is counted between a control group；Variable appropriate is carried out to the data of abnormal or heterogeneity of variance to turn
It changes, after meeting normal state or variance and requiring together, is counted with the data after conversion；If variable conversion after still be not up to normal state or
The neat purpose of variance, uses rank sum test instead and is counted.It is counted using variance analysis plus Q inspection.
5. experimental result
After experiment, the variation of each group rat index level is shown in Table 1~table 4.
Influence of 1 each group of table to rat body weight, weight gain
| Group | Number of cases | Weight (g) | Weight gain (cm) |
| Blank group | 10 | 200.8±3.61 | 44.7±4.21 |
| Model group | 10 | 256.1±3.49# | 96.2±3.12# |
| Positive controls | 10 | 204.5±0.09※ | 54.2±2.03※ |
| 1 low dose group of embodiment | 10 | 212.1±4.96※Δ | 70.2±3.62※Δ |
| 1 middle dose group of embodiment | 10 | 206.1±2.12※Δ | 55.4±1.98※Δ |
| 1 high dose group of embodiment | 10 | 200.9±1.14※& | 43.8±1.81※$ |
| Oat bran high dose group | 10 | 252.8±4.08Δ | 96.1±3.29Δ |
| Qingqian Willow leaf high dose group | 10 | 238.2±1.06※Δ | 88.9±1.80※Δ |
| Mushroom high dose group | 10 | 258.6±6.24Δ | 92.8±6.01Δ |
| Honeysuckle high dose group | 10 | 259.1±2.96Δ | 95.1±3.06Δ |
Note:#P < 0.05 compared with blank group,※P < 0.05 compared with model group,ΔCompared with 1 high dose group of embodiment p <
0.05,&P < 0.05 compared with positive controls.
Each group rat body weight, weight gain compare, and are shown in Table 1.
Model group rats weight, weight gain and blank group comparing difference are statistically significant (P < 0.05).
In weight, weight gain index, positive controls, each dosage group of embodiment 1, Qingqian Willow leaf group and model group ratio
Relatively there is statistical difference (P < 0.05).
In weight, weight gain index, each simple group, the low middle dosage of embodiment 1 with 1 high dose group ratio of embodiment
Relatively there is statistical difference (P < 0.05).
1 high dose group of embodiment weight compared with positive controls has statistical difference (P < 0.05).
2 each group rat body fat weight (testis and perinephric fat pad) of table, fat/weight compare
| Group | Epididymal adipose tissues (g) | Perirenal fat (g) | Fat/weight (%) |
| Blank group | 1.40±0.31 | 0.36±0.04 | 0.90±0.10 |
| Model group | 2.62±0.32# | 0.72±0.10# | 1.30±0.22# |
| Positive controls | 2.12±0.25※ | 0.54±0.24※ | 1.08±0.14※ |
| 1 low dose group of embodiment | 2.38±0.26※Δ | 0.60±0.12※Δ | 1.18±0.18※Δ |
| 1 middle dose group of embodiment | 2.08±0.14※Δ | 0.52±0.21※Δ | 1.10.±0.08※Δ |
| 1 high dose group of embodiment | 1.82±0.22※& | 0.40±0.11※& | 0.96.±0.06※& |
| Oat bran high dose group | 2.58±0.28Δ | 0.68±0.09Δ | 1.28±0.06Δ |
| Qingqian Willow leaf high dose group | 2.49±1.20Δ | 0.65±1.18Δ | 1.20±1.04Δ |
| Mushroom high dose group | 2.59±1.36Δ | 0.70±0.04Δ | 1.29±0.16Δ |
| Honeysuckle high dose group | 2.54±0.28Δ | 0.71±0.08Δ | 1.30±0.08Δ |
Note:#P < 0.05 compared with blank group,※P < 0.05 compared with model group,ΔCompared with 1 high dose group of embodiment p <
0.05,&P < 0.05 compared with positive controls.
Each group rat body fat weight (testis and perinephric fat pad), fat/weight compare, and are shown in Table 2.
Model group rats testis fat, perirenal fat, fat/weight and blank group comparing difference it is statistically significant (P <
0.05), hints model modeling success.
On testis fat, perirenal fat, fat/Body Mass Index, positive controls and each dosage group of embodiment 1 and model
Group, which compares, statistical difference (P < 0.05).
On testis fat, perirenal fat, fat/Body Mass Index, each simple group, the low middle dosage of embodiment 1 and implementation
1 high dose group of example relatively has statistical difference (P < 0.05).
On testis fat, perirenal fat, fat/Body Mass Index, 1 high dose group of embodiment has compared with positive controls
Statistical difference (P < 0.05).
The comparison (CFU/ml, x ± s) of 3 all kinds of intestinal microfloras of each group rat of table
| Group | Bifidobacterium | Lactic acid bacteria |
| Blank group | 10.48±0.61 | 10.06±0.88 |
| Model group | 7.28±0.54# | 7.34±0.48# |
| Positive controls | 7.86±0.96 | 8.04±1.01 |
| 1 low dose group of embodiment | 9.02±0.21※Δ& | 9.14±0.62※Δ& |
| 1 middle dose group of embodiment | 9.96±0.57※Δ& | 9.90±0.23※Δ& |
| 1 high dose group of embodiment | 10.96±0.48※& | 10.82±0.28※& |
| Oat bran high dose group | 9.24±0.36※Δ& | 9.02±0.43※Δ& |
| Qingqian Willow leaf high dose group | 8.92±0.34※Δ& | 8.89±0.33※Δ& |
| Mushroom high dose group | 9.51±0.74※Δ& | 9.61±0.32※& |
| Honeysuckle high dose group | 8.04±0.37※Δ& | 8.25±0.19※Δ& |
Note:#P < 0.05 compared with blank group,※P < 0.05 compared with model group,ΔCompared with 1 high dose group of embodiment p <
0.05,&P < 0.05 compared with positive controls.
The comparison of all kinds of intestinal microfloras of each group rat, is shown in Table 3
Bifidobacterium, lactic acid bacterium number and the statistically significant (P of blank group comparing difference in model group rats intestinal flora
< 0.05), hints model modeling success.
In addition to positive controls, each sample group bifidobacteria compared with model group has statistical difference (P < 0.05).
In addition to positive controls, each sample group lactic acid bacterium number compared with model group has statistical difference (P < 0.05).
Each simple group, the low middle dosage of embodiment 1 bifidobacteria compared with 1 high dose group of embodiment have statistics poor
Different (P < 0.05).Each simple group, the low middle dosage of embodiment 1 lactic acid bacterium number compared with 1 high dose group of embodiment have statistics
Difference (P < 0.05).
Each sample group Bifidobacterium and lactic acid bacterium number compared with positive controls have statistical difference (P < 0.05).
TC, TG, LDL, HDL comparision contents in 4 each group rat fat of table
| Group | TC(mmol/L) | TG(mmol/L) | LDL(mmol/L) | HDL(mmol/L) |
| Blank group | 1.29±0.31 | 1.03±0.15 | 1.01±0.31 | 1.81±0.19 |
| Model group | 3.81±0.29# | 2.44±0.09# | 2.81±0.42# | 0.51±0.15# |
| Positive controls | 1.81±0.30※ | 1.32±0.06※ | 1.32±0.19※ | 1.39±0.10※ |
| 1 low dose group of embodiment | 2.01±0.19※Δ | 1.61±0.23※Δ | 1.57±0.29※Δ | 1.19±0.21※Δ |
| 1 middle dose group of embodiment | 1.81±0.29※Δ | 1.27±0.19※Δ | 1.35±0.29※Δ | 1.41±0.15※Δ |
| 1 high dose group of embodiment | 1.59±0.26※& | 1.19±0.10※& | 1.18±0.19※& | 1.56±0.08※& |
| Oat bran high dose group | 2.59±0.21※Δ | 1.60±0.16※Δ | 1.76±0.21※Δ | 1.09±0.11※Δ |
| Qingqian Willow leaf high dose group | 2.19±0.18※Δ | 1.52±0.13※Δ | 1.49±0.12※Δ | 1.21±0.14※Δ |
| Mushroom high dose group | 2.22±0.41※Δ | 1.61±0.39※Δ | 1.69±0.51※Δ | 1.07±0.13※Δ |
| Honeysuckle high dose group | 2.31±0.09※Δ | 1.64±0.09※Δ | 1.80±0.10※Δ | 0.99±0.18※Δ |
Note:#P < 0.05 compared with blank group,※P < 0.05 compared with model group,ΔCompared with 1 high dose group of embodiment p <
0.05,&P < 0.05 compared with positive controls.
TC, TG, LDL, HDL comparision contents, are shown in Table 4 in each group rat fat.
In model group rats blood lipid TC, TG, LDL, HDL content and blank group comparing difference it is statistically significant (P <
0.05), hints model modeling success.
TC, TG, LDL, HDL content and model group have statistical difference (P < 0.05) in each sample group.
TC, TG, LDL, HDL content have compared with 1 high dose group of embodiment in each simple group and the low middle dosage of embodiment 1
Statistical difference (P < 0.05).
In 1 high dose group of embodiment TC, TG, LDL, HDL content have compared with positive controls statistical difference (P <
0.05)。
The 5 each group rat inflammation factor (CRP, TNF-α, IL-6) of table compares
| Group | CRP(ng/ml) | TNF-α(pg/ml) | IL-6(pg/ml) |
| Blank group | 1.24±0.31 | 199.98±8.12 | 95.12±5.23 |
| Model group | 5.80±0.51# | 499.91±9.35#Δ | 259.02±4.6# |
| Positive controls | 2.79±0.29※ | 259.63±7.45※ | 160.71±5.36※ |
| 1 low dosage of embodiment | 3.51±0.41※Δ | 299.87±10.40※Δ | 179.14±6.31※Δ |
| 1 middle dosage of embodiment | 2.79±0.50※Δ | 259.81±9.01※Δ | 156.81±7.14※Δ |
| 1 high dose of embodiment | 2.19±0.19※& | 228.52±7.26&※ | 137.42±4.82※& |
| Oat bran high dose | 4.14±0.09※Δ | 310.71±9.22※Δ | 189.94±8.41※Δ |
| Qingqian Willow leaf high dose | 3.49±0.31※Δ | 279.19±6.54※Δ | 170.61±5.54※Δ |
| Mushroom high dose group | 3.97±0.22※Δ | 289.83±9.36※Δ | 179.91±7.48※Δ |
| Honeysuckle high dose group | 4.21±0.20※Δ | 305.41±6.71※Δ | 186.237±9.14※Δ |
Note:#P < 0.05 compared with blank group,※P < 0.05 compared with model group,ΔCompared with 1 high dose group of embodiment p <
0.05,&P < 0.05 compared with positive controls.
The each group rat inflammation factor (CRP, TNF-α, IL-6) compares, and is shown in Table 5.
Model group rats inflammatory factor (CRP, TNF-α, IL-6) and blank group comparing difference it is statistically significant (P <
0.05), hints model modeling success.
The value of CRP, TNF-α, IL-6 have statistical difference (P < 0.05) compared with model group in each sample group.
CRP, 1 high dose group ratio of TNF-α, the value of IL-6 and embodiment in each simple group and the low middle dose group of embodiment 1
Relatively there is statistical difference (P < 0.05).
In 1 high dose group of embodiment CRP, TNF-α, the value of IL-6 have compared with positive controls statistical difference (P <
0.05)。
6. testing brief summary
In summary data are analyzed, and experimental animal is after modeling, weight, weight gain, body fat weight (testis and kidney
Peripheral adipose pad), fat/weight, Bifidobacterium and lactic acid bacterium number, blood lipid (TC, TG, LDL, HDL), inflammatory factor (CRP,
TNF-α, IL-6) relative to blank group, there is significant difference, prompt modeling success.And except each dosage group of embodiment 1 to
Upper index has significant improvement effect, and each sample group is prompted to have preventive and therapeutic effect to hyperlipidemia and obesity as prebiotics.Simultaneously
Under same dose, implements 1 high dose group and each simple group and positive drug group are better than to the above target improvement significant effect, prompt
Implementing 1 composition is more preferably to select.
The effect experiment of 11 prebiotic compositions Weight-reducing and lipid-lowering of embodiment
Experimental method is referring to embodiment 6.The given the test agent of various dose is given in each sample group stomach-filling, embodiment 1 is low, in,
High dose group 0.9g/kg, 1.8g/kg, 3.6g/kg, embodiment 2,3,4 high dose group 3.6g/kg, administered volume 2.0ml/
kg.Experimental result is shown in Table 6~table 10.
Influence of 6 each group of table to rat body weight, weight gain
| Group | Number of cases | Weight | Weight gain (cm) |
| Blank group | 10 | 200.8±3.61 | 44.7±4.21 |
| Model group | 10 | 256.1±3.49# | 96.2±3.12# |
| 1 high dose group of embodiment | 10 | 200.9±1.14※ | 43.8±1.81※ |
| 2 high dose group of embodiment | 10 | 207.3±1.91※ | 68.3±1.42※ |
| 3 high dose group of embodiment | 10 | 210.1±0.63※ | 69.6±2.25※ |
| 4 high dose group of embodiment | 10 | 214.0±1.08※ | 70.8±3.61※ |
Note:#P < 0.05 compared with blank group,※P < 0.05 compared with model group.
Each group rat body weight, weight gain compare, and are shown in Table 6.
Model group rats weight, weight gain and blank group comparing difference are statistically significant (P < 0.05).Each sample group
Weight has statistical difference (P < 0.05) compared with model group.Each sample group weight gain compared with model group has statistical difference
(P<0.05)。
7 each group rat body fat weight (testis and perinephric fat pad) of table, fat/weight compare
| Group | Epididymal adipose tissues (g) | Perirenal fat (g) | Fat/weight (%) |
| Blank group | 1.40±0.31 | 0.36±0.04 | 0.90±0.10 |
| Model group | 2.62±0.32# | 0.72±0.10# | 1.30±0.22# |
| 1 high dose group of embodiment | 1.82±0.22※ | 0.40±0.11※ | 0.96.±0.06※ |
| 2 high dose group of embodiment | 1.99±0.41※Δ | 0.60±0.23※Δ | 1.15.±0.06※Δ |
| 3 high dose group of embodiment | 2.16±0.36※Δ | 0.62±0.10※Δ | 1.16±0.25※Δ |
| 4 high dose group of embodiment | 2.19±0.52※Δ | 0.61±0.13※Δ | 1.13±0.24※Δ |
Note:#P < 0.05 compared with blank group,※P < 0.05 compared with model group,ΔCompared with 1 high dose group of embodiment p <
0.05。
Each group rat body fat weight (testis and perinephric fat pad), fat/weight compare, and are shown in Table 7.
Model group rats testis fat, perirenal fat, fat/weight and blank group comparing difference it is statistically significant (P <
0.05), hints model modeling success.
Each sample group testis fat compared with model group has statistical difference (P < 0.05).Each sample group is compared with model group
Perirenal fat has statistical difference (P < 0.05).Each sample group is fatty compared with model group/weight have statistical difference (P <
0.05)。
Each sample group testis fat compared with 1 high dose group of embodiment has statistical difference (P < 0.05).Each sample group with
1 high dose group of embodiment, which compares perirenal fat, statistical difference (P < 0.05).Each sample group is compared with 1 high dose group of embodiment
Fat/weight has statistical difference (P < 0.05).
The comparison (CFU/ml, x ± s) of 8 all kinds of intestinal microfloras of each group rat of table
| Group | Bifidobacterium | Lactic acid bacteria |
| Blank group | 1048±061 | 10.06±0.88 |
| Model group | 7.28±0.54# | 7.34±0.48# |
| 1 high dose group of embodiment | 10.96±0.48※& | 10.82±0.28※& |
| 2 high dose group of embodiment | 10.74±0.81※ | 10.53±0.36※ |
| 3 high dose group of embodiment | 10.18±0.52※ | 9.86±0.49※ |
| 4 high dose group of embodiment | 10.86±0.76※ | 10.49±0.55※ |
Note:#P < 0.05 compared with blank group,※P < 0.05 compared with model group,ΔCompared with 1 high dose group of embodiment p <
0.05。
The comparison of all kinds of intestinal microfloras of each group rat, is shown in Table 8
Bifidobacterium, lactic acid bacterium number and the statistically significant (P of blank group comparing difference in model group rats intestinal flora
< 0.05), hints model modeling success.
In addition to 1 low dose group of embodiment, each sample group bifidobacteria compared with model group have statistical difference (P <
0.05).Each sample group lactic acid bacterium number compared with model group has statistical difference (P < 0.05).
TC, TG, LDL, HDL comparision contents in 9 each group rat fat of table
| Group | TC(mmol/L) | TG(mmol/L) | LDL(mmol/L) | HDL(mmol/L) |
| Blank group | 1.29±0.31 | 1.03±0.15 | 1.01±0.31 | 1.81±0.19 |
| Model group | 3.81±0.29# | 2.44±0.09# | 2.81±0.42# | 0.51±0.15# |
| 1 high dose group of embodiment | 1.59±0.26※& | 1.19±0.10※& | 1.18±0.19※& | 1.56±0.08※& |
| 2 high dose group of embodiment | 1.69±0.23※Δ | 1.31±0.08※Δ | 1.29±0.09※Δ | 1.46±0.10※Δ |
| 3 high dose group of embodiment | 1.75±0.32※Δ | 1.27±0.06※Δ | 1.28±0.19※Δ | 1.41±0.11※Δ |
| 4 high dose group of embodiment | 1.71±0.08※Δ | 1.27±0.11※Δ | 1.27±0.28※Δ | 1.39±0.09※Δ |
Note:#P < 0.05 compared with blank group,※P < 0.05 compared with model group,ΔCompared with 1 high dose group of embodiment p <
0.05。
TC, TG, LDL, HDL comparision contents, are shown in Table 9 in each group rat fat.
In model group rats blood lipid TC, TG, LDL, HDL content and blank group comparing difference it is statistically significant (P <
0.05), hints model modeling success.
Each sample group TC compared with model group has statistical difference (P < 0.05).Each sample group TG compared with model group has system
Meter learns difference (P < 0.05).Each sample group LDL compared with model group has statistical difference (P < 0.05).Each sample group and model group
Comparing HDL has statistical difference (P < 0.05).
Each sample group TC compared with 1 high dose group of embodiment has statistical difference (P < 0.05).Each sample group and embodiment 1
High dose group, which compares TG, statistical difference (P < 0.05).Each sample group LDL compared with 1 high dose group of embodiment has statistics poor
Different (P < 0.05).Each sample group HDL compared with 1 high dose group of embodiment has statistical difference (P < 0.05).
10 each group rat glycosylated hemoglobin of table, inflammatory factor (CRP, TNF-α, IL-6) compare
| Group | CRP(ng/ml) | TNF-α(pg/ml) | IL-6(pg/ml) |
| Blank group | 1.24±0.31 | 199.98±8.12 | 95.12±5.23 |
| Model group | 5.80±0.51# | 499.91±9.35#Δ | 259.02±4.6# |
| 1 high dose group of embodiment | 2.19±0.19※& | 228.52±7.26&※ | 137.42±4.82※& |
| 2 high dose group of embodiment | 2.91±0.39※Δ | 266.94±8.96※Δ | 159.36±7.61※Δ |
| 3 high dose group of embodiment | 2.84±0.19※Δ | 269.36±5.21※Δ | 149.97±4.87※Δ |
| 4 high dose group of embodiment | 2.81±0.28※Δ | 257.95±6.87※Δ | 156.86±3.79※Δ |
Note:#P < 0.05 compared with blank group,※P < 0.05 compared with model group,ΔCompared with 1 high dose group of embodiment p <
0.05。
The each group rat inflammation factor (CRP, TNF-α, IL-6) compares, and is shown in Table 10.
Model group rats inflammatory factor (CRP, TNF-α, IL-6) and blank group comparing difference it is statistically significant (P <
0.05), hints model modeling success.
Each sample group TNF-α compared with model group has statistical difference (P < 0.05).Each sample group IL- compared with model group
6 have statistical difference (P < 0.05).Each sample group CRP compared with model group has statistical difference (P < 0.05).
Each sample group TNF-α compared with 1 high dose group of embodiment has statistical difference (P < 0.05).Each sample group and implementation
1 high dose group of example, which compares IL-6, statistical difference (P < 0.05).Each sample group CRP compared with 1 high dose group of embodiment has system
Meter learns difference (P < 0.05).
6. testing brief summary
In summary data are analyzed, and experimental animal is after modeling, weight, weight gain, body fat weight (testis and kidney
Peripheral adipose pad), fat/weight, blood lipid (TC, TG, LDL, HDL), inflammatory factor (TNF-α, IL-6, CRP), Bifidobacterium and
Lactic acid bacterium number has significant difference relative to blank group, prompts modeling success.And composition each sample group is to the above index
There is significant improvement effect, prompts each sample group that there is preventive and therapeutic effect to promotion growth of probiotics, lower blood-fat and reduce weight.
Embodiment 12
Experimental method investigates the drug effect of the multiple combinations of each Chinese medical extract referring to embodiment 6.Experimental result is shown in Table 11~
Table 14.
Influence of 11 each group of table to rat body weight, weight gain
| Sequence | Group | Number of cases | Weight | Weight gain |
| 1 | Blank group | 10 | 200.8±3.61 | 44.7±4.21 |
| 2 | Model group | 10 | 256.1±3.49# | 96.2±3.12# |
| 3 | 1 high dose group of embodiment | 10 | 200.9±1.14※ | 43.8±1.81※ |
| 4 | 50 parts of 50 parts+Qingqian Willow leaf of oat bran | 10 | 239.1±2.12※Δ | 86.3±4.33※Δ |
| 5 | 50 parts of 50 parts+mushroom of oat bran | 10 | 240.2±1.06※Δ | 90.1±2.11※Δ |
| 6 | 50 parts of 50 parts+honeysuckle of oat bran | 10 | 248.6±1.83※Δ | 90.8±7.01※Δ |
| 7 | 50 parts of 50 parts+mushroom of Qingqian Willow leaf | 10 | 237.1±1.36※Δ | 85.1±1.01※Δ |
| 8 | 50 parts of 50 parts+honeysuckle of Qingqian Willow leaf | 10 | 238.8±2.18※Δ | 86.0±2.31※Δ |
| 9 | 50 parts of 50 parts+mushroom of honeysuckle | 10 | 241.3±1.72※v | 89.3±1.63※Δ |
| 10 | 50 parts of 50 parts+mushroom of 50 parts+Qingqian Willow leaf of oat bran | 10 | 229.1±2.15※Δ | 78.8±2.10※Δ |
| 11 | 50 parts of 50 parts+honeysuckle of 50 parts+Qingqian Willow leaf of oat bran | 10 | 230.1±1.96※v | 79.1±1.69※v |
| 12 | 50 parts of 50 parts+honeysuckle of 50 parts+mushroom of Qingqian Willow leaf | 10 | 228.8±2.53※Δ | 76.1±2.31※v |
| 13 | 50 parts of 50 parts+honeysuckle of 50 parts+mushroom of oat bran | 10 | 235.9±2.52※Δ | 88.5±3.02※Δ |
Note:ΔIndicate p < 0.05 compared with 1 high dose group of embodiment,※P < 0.05 compared with model group.
12 each group rat body fat weight (testis and perinephric fat pad) of table, fat/weight compare
| Serial number | Epididymal adipose tissues (g) | Perirenal fat (g) | Fat/weight (%) |
| 1 | 1.40±0.31 | 0.36±0.04 | 0.90±0.10 |
| 2 | 2.62±0.32# | 0.72±0.10# | 1.30±0.22# |
| 3 | 1.82±0.22※ | 0.40±0.11※ | 0.96.±0.06※ |
| 4 | 2.41±1.22Δ | 0.67±1.12Δ | 1.26±1.32Δ |
| 5 | 2.43±1.14Δ | 0.66±1.21Δ | 1.28.±1.07Δ |
| 6 | 2.52±0.41Δ | 0.69±0.14Δ | 1.30.±0.09Δ |
| 7 | 2.58±0.69Δ | 0.68±0.29Δ | 1.28±0.76Δ |
| 8 | 2.51±1.20Δ | 0.69±1.18Δ | 1.29±1.04Δ |
| 9 | 2.59±1.36Δ | 0.71±0.06Δ | 1.31±0.04Δ |
| 10 | 2.09±0.17※Δ | 0.56±0.08※Δ | 1.01±0.11※Δ |
| 11 | 2.01±0.08※Δ | 0.53±0.11※Δ | 1.03±0.07※Δ |
| 12 | 1.99±0.21※Δ | 0.49±0.27※Δ | 0.99±0.10※Δ |
| 13 | 2.12±0.09※Δ | 0.52±0.19※Δ | 1.07±0.17※Δ |
Note: sequence number counter sample group and table 11 are consistent in table 12；ΔIndicate compared with 1 high dose group of embodiment p <
0.05,※P < 0.05 compared with model group.
The comparison (CFU/ml, x ± s) of 13 all kinds of intestinal microfloras of each group rat of table
| Group | Lactic acid bacteria | Bifidobacterium |
| 1 | 10.48±0.61 | 10.06±0.88 |
| 2 | 7.28±0.54# | 7.34±0.48# |
| 3 | 10.96±0.48※ | 10.82±0.28※ |
| 4 | 8.96±0.12※Δ | 9.09±0.53※Δ |
| 5 | 8.98±0.36※Δ | 9.03±0.47※Δ |
| 6 | 9.07±0.51※Δ | 8.99±0.37※Δ |
| 7 | 9.05±0.61※Δ | 8.98±0.65※Δ |
| 8 | 9.09±0.49※Δ | 9.01±0.33※Δ |
| 9 | 9.01±0.51※Δ | 9.02±0.42※Δ |
| 10 | 9.94±0.52※Δ | 10.25±0.19※Δ |
| 11 | 9.87±0.59※Δ | 9.96±0.62※Δ |
| 12 | 10.04±0.61※Δ | 9.90±0.23※Δ |
| 13 | 9.93±0.71※Δ | 9.92±0.28※Δ |
Note: sequence number counter sample group and table 11 are consistent in table 13；ΔIndicate compared with 1 high dose group of embodiment p <
0.05,※P < 0.05 compared with model group.
TC, TG, LDL, HDL content and inflammatory factor compare in 14 each group blood lipid of table
| Serial number | TC | TG | LDL | HDL | CRP | TNF-α | IL-6(pg/ml) |
| 1 | 1.29±0.31 | 1.03±0.15 | 1.01±0.31 | 1.81±0.19 | 1.24±0.31 | 199.98±8.12 | 95.12±5.23 |
| 2 | 3.81±0.29# | 2.44±0.09# | 2.81±0.42# | 0.51±0.15# | 5.80±0.51# | 499.91±9.35 | 259.02±4.6# |
| 3 | 1.59±0.26※& | 1.19±0.10※& | 1.18±0.19※& | 1.56±0.08※& | 2.19±0.19※& | 228.52±7.26& | 137.42±4.82※ |
| 4 | 2.20±0.39※Δ | 1.58±0.20※Δ | 1.59±0.23※Δ | 1.10±0.41※Δ | 3.80±0.31※Δ | 284.67±8.97※Δ | 176.81±8.06※Δ |
| 5 | 2.21±0.12※Δ | 1.59±0.27※Δ | 1.60±0.20※Δ | 1.09±0.41※Δ | 3.79±0.45※Δ | 295.62±9.08※Δ | 183.48±6.46※Δ |
| 6 | 2.19±0.52※Δ | 1.60±0.45※Δ | 1.59±0.32※Δ | 1.03±0.24※Δ | 3.81±0.36※Δ | 299.04±8.85※Δ | 182.68±8.50※Δ |
| 7 | 2.21±0.19※Δ | 1.60±0.11※Δ | 1.62±0.31※Δ | 1.02±0.26※Δ | 3.83±0.40※Δ | 286.16±7.91※Δ | 176.49±9.57※Δ |
| 8 | 2.15±0.91※Δ | 1.59±0.28※Δ | 1.60±0.49※Δ | 1.01±0.37※Δ | 3.78±0.47※Δ | 285.54±8.35※Δ | 175.11±9.65※Δ |
| 9 | 2.17±0.87※Δ | 1.60±0.10※Δ | 1.58±0.27※Δ | 0.99±0.18※Δ | 3.80±0.12※Δ | 293.62±8.26※Δ | 181.72±8.35※Δ |
| 10 | 2.01±0.21※Δ | 1.55±0.08※Δ | 1.51±0.35※Δ | 1.28±0.35※Δ | 3.02±0.38※Δ | 280.96±7.61※Δ | 169.83±5.96※Δ |
| 11 | 1.99±0.19※Δ | 1.53±0.21※Δ | 1.52±0.47※Δ | 1.25±0.42※Δ | 2.99±0.20※Δ | 279.27±3.52※Δ | 170.84±6.23※Δ |
| 12 | 1.98±0.35※Δ | 1.53±0.51※Δ | 1.49±0.12※Δ | 1.22±0.37※Δ | 2.97±0.53※Δ | 273.65±6.95※Δ | 171.05±4.07※Δ |
| 13 | 2.02±0.25※Δ | 1.56±0.07※Δ | 1.50±0.09※Δ | 1.23±0.26※Δ | 3.04±0.11※Δ | 276.51±8.12※Δ | 167.91±7.96※Δ |
Note: sequence number counter sample group and table 9 are consistent in table 12；ΔIndicate p < 0.05 compared with 1 high dose group of embodiment,※
P < 0.05 compared with model group.
Interpretation of result:
In summary data are analyzed, and are compared with 1 high dose group of embodiment, and variant simple, which combines more each index, to be had
The significance of difference.As a result prompt 1 formula combination of embodiment is aobvious in Weight-reducing and lipid-lowering, the growth of promotion beneficial bacterium, the effect of anti-inflammatory aspect
It writes.
Embodiment 13
A kind of drug, the drug are oral agents: including prebiotic compositions 1 and glucose.
Embodiment 14
Acceptable food additives on a kind of health food, including prebiotic compositions 1 and food.
Said medicine and health food can lose weight, reduce weight gain, reduce body fat weight (testis and kidney week
Enclose fat pad), improve Bifidobacterium and lactic acid bacteria ratio, adjust inflammatory factor (TNF-α, IL-6, CRP), improve blood lipid (TC,
TG, LDL, HDL), it can be used for Weight-reducing and lipid-lowering, significant effect is better than the effect of each single dose.
Other unspecified parts are the prior art.Although above-described embodiment is made that the present invention and retouches in detail
State, but it is only a part of the embodiment of the present invention, rather than whole embodiments, people can also according to the present embodiment without
Other embodiments are obtained under the premise of creativeness, these embodiments belong to the scope of the present invention.
Claims (10)
1. a kind of Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions, it is characterised in that: the raw material of the composition is by oat bran, green money
Willow leaf, mushroom and honeysuckle composition, in parts by weight, the dosage of each raw material are as follows:
2. wanting the 1 Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions according to right, it is characterised in that: in the composition, with weight
Part meter, the dosage of each raw material are as follows:
3. Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions according to claim 1 or claim 2, it is characterised in that: in the composition, with
Parts by weight meter, the dosage of each raw material are as follows:
4. the preparation method of Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions, feature described in a kind of claims 1 to 3 any one exist
In: the following steps are included:
1) oat bran, Qingqian Willow leaf, mushroom and honeysuckle are mixed first, obtains mixture；
2) it soaks in water, decocts into mixture, filtering obtains the Chinese medicine composition.
5. the preparation method of Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions according to claim 4, it is characterised in that: the step
2) in, the dosage of water is 3~10 times of mixture；
The time of immersion is 0.25~2 hour,
The number of decoction is 1~5 time, and the time decocted every time is 1~4 hour.
6. drug or guarantor that composition described in a kind of claims 1 to 3 any one adjusts intestinal flora Weight-reducing and lipid-lowering in preparation
Application in health food.
7. a kind of drug, it is characterised in that: including composition described in any one of claims 1 to 3.
8. drug according to claim 7, it is characterised in that: the drug further includes pharmaceutically acceptable auxiliary material.
9. a kind of health food, it is characterised in that: including claim 1~: composition described in any one of 3.
10. health food according to claim 9, it is characterised in that: the health food further includes acceptable on food
Food additives.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910858450.7A CN110464808A (en) | 2019-09-11 | 2019-09-11 | Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910858450.7A CN110464808A (en) | 2019-09-11 | 2019-09-11 | Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110464808A true CN110464808A (en) | 2019-11-19 |
Family
ID=68515578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910858450.7A Pending CN110464808A (en) | 2019-09-11 | 2019-09-11 | Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110464808A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113750113A (en) * | 2020-06-01 | 2021-12-07 | 山东新时代药业有限公司 | Composition of probiotics and prebiotics and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103169125A (en) * | 2013-03-08 | 2013-06-26 | 云和康泰农业科技有限公司 | Nutritional beverage and its preparation method |
| CN105494814A (en) * | 2015-12-30 | 2016-04-20 | 桂林双象生物科技有限公司 | Honeysuckle and cyclocarya paliurus substitutional tea and preparation method thereof |
| CN108926627A (en) * | 2017-05-25 | 2018-12-04 | 无限极（中国）有限公司 | A kind of wet composition of eliminating the phlegm and its preparation method and application |
-
2019
- 2019-09-11 CN CN201910858450.7A patent/CN110464808A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103169125A (en) * | 2013-03-08 | 2013-06-26 | 云和康泰农业科技有限公司 | Nutritional beverage and its preparation method |
| CN105494814A (en) * | 2015-12-30 | 2016-04-20 | 桂林双象生物科技有限公司 | Honeysuckle and cyclocarya paliurus substitutional tea and preparation method thereof |
| CN108926627A (en) * | 2017-05-25 | 2018-12-04 | 无限极（中国）有限公司 | A kind of wet composition of eliminating the phlegm and its preparation method and application |
Non-Patent Citations (5)
| Title |
|---|
| 任广旭、文洁: "《肠道菌群与精准营养健康》", 31 March 2019, 中国科学技术出版社 * |
| 文燕、丁仕武: "《神奇的青钱柳与糖尿病》", 28 February 2015, 军事医学科学出版社 * |
| 段翠翠: "《肠胃病怎么吃随身查》", 30 September 2013, 天津科学技术出版社 * |
| 沈丕安: "《中华本草》", 30 September 2017, 上海科学普及出版社 * |
| 爆炸营养课堂: "天天吃燕麦麸皮能减肥？不说还真不知道，原来真有这些好处", 《HTTPS://BAIJIAHAO.BAIDU.COM/S?ID=1596170384063414950&WFR=SPIDER&FOR=PC，天天吃燕麦麸皮能减肥？不说还真不知道，原来真有这些好处》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113750113A (en) * | 2020-06-01 | 2021-12-07 | 山东新时代药业有限公司 | Composition of probiotics and prebiotics and application thereof |
| CN113750113B (en) * | 2020-06-01 | 2022-12-02 | 山东新时代药业有限公司 | Composition of probiotics and prebiotics and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6271571B2 (en) | Composition for maintaining intestinal microbiota equilibrium, process for producing the composition, and use of the composition | |
| US10959452B2 (en) | Composition for induced bowel movement and diet and preparation method thereof | |
| CN104642870B (en) | A kind of prebiotic compositions | |
| CN103648512B (en) | The bacterium bacterial strain for belonging to Bifidobacterium for the treatment of hypercholesterolemia | |
| CN106174585A (en) | Hypoglycemic compositions and hypoglycemic compound probiotic spy's dietary seafood | |
| CN101744239A (en) | Application of dietary fibers in the preparation of pharmaceutical preparations for preventing and curing excrement smelling or excrement smelling poisoning syndrome | |
| CN106729092A (en) | A kind of blood fat reducing preparation containing xylo-oligosaccharide and its preparation method and application | |
| CN106942724A (en) | Composition acted on regulating intestinal canal Bacterial community and preparation method and application | |
| CN101416747A (en) | A kind of solid low-energy food that is rich in dietary fiber and preparation method thereof | |
| CN105982009A (en) | Composition for regulating human body intestinal micro-ecology | |
| CN107259287B (en) | Solid beverage capable of remarkably promoting growth of intestinal probiotics and preparation method of solid beverage | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| CN110024932A (en) | A kind of black fungus extract solid drink formula and preparation method thereof for losing weight, improving diarrhea, adjust flora | |
| CN106723015A (en) | A kind of health food and its preparation technology with antifatigue and anti-oxidation function | |
| CN112970990A (en) | Probiotic solid beverage with weight-losing and lipid-lowering effects and preparation process thereof | |
| CN109010420A (en) | A kind of purposes of Rhizoma Chuanxiong and pueraria lobata Pharmaceutical composition in the food or drug that preparation improves intestinal environment | |
| CN105661515A (en) | Enzyme lozenges for three-hypers and preparation method thereof | |
| CN110075226A (en) | It is a kind of can be with the probiotic composition of reducing blood lipid | |
| CN106465946A (en) | A kind of loosening bowel to relieve constipation dietary fiber | |
| CN112931883A (en) | Prebiotic composition and preparation method and application thereof | |
| CN110464808A (en) | Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions and its preparation method and application | |
| CN107136513A (en) | Adjust the health food of colony balance, preparation method and applications in human body | |
| CN101297820A (en) | Streptococcus faecium function signal molecule formulation and product thereof for reducing fat and slimming | |
| CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
| CN109965290B (en) | Meal replacement powder for improving intestinal flora and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191119 |